Share on StockTwits

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) major shareholder Francis Reynolds unloaded 25,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $2.23, for a total value of $55,750.00. Following the completion of the sale, the insider now directly owns 9,936,420 shares in the company, valued at approximately $22,158,217. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) traded up 3.62% during mid-day trading on Friday, hitting $2.29. 56,958 shares of the company’s stock traded hands. Invivo Therapeutics Holdings Corp has a 1-year low of $0.94 and a 1-year high of $6.20. The stock’s 50-day moving average is $2.25 and its 200-day moving average is $2.24. The company’s market cap is $180.3 million.

Separately, analysts at Aegis cut their price target on shares of Invivo Therapeutics Holdings Corp from $7.00 to $4.00 in a research note to investors on Monday, November 25th. They now have a “buy” rating on the stock.

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.